Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.